利妥昔单抗治疗难治性中重度天疱疮的长期经验数据集

资源简介

利妥昔单抗治疗难治性中重度天疱疮的长期经验数据集

【数据集背景】

本数据集源站标题为《Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus》。配套论文《Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus》发表于 Journal of Dermatological Treatment（2021），DOI：10.1080/09546634.2021.1919288。源站首次发布：2021-06-08。

【数据内容】

源站原始描述：Rituximab appears to be effective for treating pemphigus, although there are limited long-term data. This retrospective single-center study evaluated patients with conventional treatment-resistant pemphigus who received rituximab during September 2010–December 2019. The first rituximab cycle was based on the rheumatoid arthritis protocol in all patients except one patient, and additional single doses (500 mg or 1000 mg) were administered after clinical and/or serological relapse. The consensus d…

【数据结构与技术规格】

文件数 2 个，合计 313.06 KB。IJDT_A_1919288_SuppTable1.pdf：application/pdf，207.18 KB。IJDT_A_1919288_SuppTable2.pdf：application/pdf，105.88 KB。数据集 DOI：10.6084/m9.figshare.14645316。

【主题与分类】

源站学科分类：Space Science、Medicine、Pharmacology、Biotechnology、Ecology、Mathematical Sciences not elsewhere classified。主题标签：Rituximab、pemphigus、long-term efficacy、long-term safety。

【适用方向】

源站学科分类标注为 Space Science、Medicine、Pharmacology、Biotechnology、Ecology、Mathematical Sciences not elsewhere classified。

【获取与许可】

源站页面：https://tandf.figshare.com/articles/dataset/Long-term_experience_with_rituximab_therapy_for_treatment-resistant_moderate-to-severe_pemphigus/14645316

使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。

规范引用：Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus. Taylor & Francis. Bozca, Burçin Cansu; Bilgiç, Aslı; Uzun, Soner

【使用注意】

· 源站最后修改于 2026-07-22，引用时请注意版本时效。